HK1254289A1 - 調控免疫反應的方法及抗體 - Google Patents
調控免疫反應的方法及抗體Info
- Publication number
- HK1254289A1 HK1254289A1 HK18113250.8A HK18113250A HK1254289A1 HK 1254289 A1 HK1254289 A1 HK 1254289A1 HK 18113250 A HK18113250 A HK 18113250A HK 1254289 A1 HK1254289 A1 HK 1254289A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- immunoresponse
- antibodies
- modulation
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562174673P | 2015-06-12 | 2015-06-12 | |
US201562174681P | 2015-06-12 | 2015-06-12 | |
PCT/CN2016/085451 WO2016197974A1 (en) | 2015-06-12 | 2016-06-12 | Methods and antibodies for modulation of immunoresponse |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1254289A1 true HK1254289A1 (zh) | 2019-07-19 |
Family
ID=57502886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18113250.8A HK1254289A1 (zh) | 2015-06-12 | 2018-10-16 | 調控免疫反應的方法及抗體 |
Country Status (10)
Country | Link |
---|---|
US (3) | US11685785B2 (zh) |
EP (2) | EP3307782A4 (zh) |
JP (2) | JP2018524299A (zh) |
KR (4) | KR20180012856A (zh) |
CN (2) | CN108135961A (zh) |
AU (2) | AU2016276509B2 (zh) |
CA (2) | CA2988623C (zh) |
HK (1) | HK1254289A1 (zh) |
RU (2) | RU2734169C2 (zh) |
WO (2) | WO2016197975A1 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3665202A1 (en) * | 2017-08-09 | 2020-06-17 | Massachusetts Institute Of Technology | Albumin binding peptide conjugates and methods thereof |
CN111615386A (zh) * | 2017-11-03 | 2020-09-01 | 台湾基督长老教会马偕医疗财团法人马偕纪念医院 | 调节肿瘤相关髓样细胞及增强免疫检查点阻断的方法 |
WO2019232132A1 (en) * | 2018-05-30 | 2019-12-05 | The Regents Of The University Of California | Methods of enhancing immunity |
CN110711205A (zh) * | 2018-07-13 | 2020-01-21 | 北京中台恒基生物技术有限公司 | 一种肿瘤疫苗及其制备方法 |
TW202019469A (zh) * | 2018-08-09 | 2020-06-01 | 英屬開曼群島商先知生物科技股份有限公司 | 抑制b型肝炎病毒複製及b型肝炎表面抗原分泌之方法 |
CN110407865B (zh) * | 2019-08-02 | 2022-04-15 | 山东师范大学 | 基于苯磺酰胺结构的式(i)化合物及其制备方法与应用 |
CN111647084B (zh) * | 2020-06-13 | 2020-12-01 | 广东赛尔生物科技有限公司 | 抗c-MET抗体及其在治疗癌症中的应用 |
WO2022011021A1 (en) * | 2020-07-07 | 2022-01-13 | Ascendo Biotechnology, Inc. | Use of conserved peptide epitopes from sars-cov-2 for the development of a broad covid-19 vaccine |
AU2022243562A1 (en) * | 2021-03-26 | 2023-10-12 | The General Hospital Corporation | Humanized mab107 |
EP4265248A1 (en) * | 2022-04-22 | 2023-10-25 | Université Paris Cité | Compounds inducing production of proteins by immune cells |
WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5921534A (en) | 1997-07-03 | 1999-07-13 | Chick Workholding Solutions, Inc. | Detachable jaw for vise-like workholding apparatus |
EP2206517B1 (en) | 2002-07-03 | 2023-08-02 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
US20040180409A1 (en) * | 2003-03-16 | 2004-09-16 | Mcvicar Daniel | TLT-1, a novel platelet-associated receptor and uses therefor |
ATE551339T1 (de) | 2003-11-05 | 2012-04-15 | Sarcode Bioscience Inc | Modulatoren der zellulären adhäsion |
GB0507918D0 (en) | 2005-04-19 | 2005-05-25 | Novartis Ag | Organic compounds |
EP2161336B2 (en) | 2005-05-09 | 2017-03-29 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
GB0520378D0 (en) | 2005-10-06 | 2005-11-16 | Novartis Ag | Organic compounds |
EP1951665A1 (en) | 2005-11-14 | 2008-08-06 | Dominion Pharmakine S.L. | Novel inhibitors of the lfa-1/icam-1 interaction, and uses thereof |
EP2079483A4 (en) * | 2006-07-29 | 2010-10-20 | Robert Lamar Bjork Jr | BISPECIFIC MONOCLONAL ANTIBODIES (SPECIFIC FOR CD3 AND CD11B) THERAPEUTIC MEDICAMENTS |
US7553936B2 (en) | 2006-12-04 | 2009-06-30 | The United States of America as represented by Secretary Department of Health and Human Services | Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions |
WO2008082537A2 (en) | 2006-12-19 | 2008-07-10 | The General Hospital Corporation | Compounds for modulating integrin cd11b/cd18 |
CN102131828B (zh) | 2007-06-18 | 2015-06-17 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
WO2010017083A1 (en) * | 2008-08-04 | 2010-02-11 | Wayne State University | Methods of treating cancer with cd11b antibodies |
CA2795390C (en) * | 2010-04-08 | 2020-11-03 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof |
TW201138808A (en) * | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
MX2013009862A (es) * | 2011-03-02 | 2013-10-25 | Novo Nordisk As | Factor de coagulacion dirigido al transcripto 1 tipo trem (tlt-1) en plaquetas activadas. |
EA027623B1 (ru) * | 2011-03-31 | 2017-08-31 | Инсэрм (Инститют Насиональ Де Ля Сантэ Э Де Ля Решерш Медикаль) | Антитела, направленные против icos, и их применения |
JP2015517463A (ja) * | 2012-05-02 | 2015-06-22 | ニューヨーク・ユニバーシティ | 黄色ブドウ球菌感染および関連状態を処置および予防する方法 |
US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
RS60421B1 (sr) * | 2012-09-07 | 2020-07-31 | Inserm (Institut National De La Santé Et De La Rech Médicale) | Inhibitorni peptidi poreklom od aktivirajućeg receptora eksprimiranog na mijeloidnim ćelijama-1 (trem-1) i trem-sličnog transkripta 1 (tlt-1) i njihove upotrebe |
RU2652876C1 (ru) * | 2016-12-21 | 2018-05-03 | Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Нижегородский государственный университет им. Н.И. Лобачевского" | Рекомбинантное антитело, специфичное к фактору некроза опухоли и маркеру иммунных клеток миелоидного ряда |
-
2016
- 2016-06-12 KR KR1020187000986A patent/KR20180012856A/ko active IP Right Grant
- 2016-06-12 EP EP16806872.4A patent/EP3307782A4/en active Pending
- 2016-06-12 KR KR1020187001000A patent/KR20180017152A/ko not_active Application Discontinuation
- 2016-06-12 AU AU2016276509A patent/AU2016276509B2/en active Active
- 2016-06-12 CA CA2988623A patent/CA2988623C/en active Active
- 2016-06-12 AU AU2016274175A patent/AU2016274175B2/en not_active Withdrawn - After Issue
- 2016-06-12 JP JP2017564350A patent/JP2018524299A/ja active Pending
- 2016-06-12 WO PCT/CN2016/085452 patent/WO2016197975A1/en active Application Filing
- 2016-06-12 WO PCT/CN2016/085451 patent/WO2016197974A1/en active Application Filing
- 2016-06-12 US US15/735,912 patent/US11685785B2/en active Active
- 2016-06-12 JP JP2017564363A patent/JP7284557B2/ja active Active
- 2016-06-12 CN CN201680034380.8A patent/CN108135961A/zh active Pending
- 2016-06-12 KR KR1020237019046A patent/KR102661066B1/ko active IP Right Grant
- 2016-06-12 KR KR1020227000032A patent/KR20220005627A/ko not_active IP Right Cessation
- 2016-06-12 US US15/735,949 patent/US20180141991A1/en not_active Abandoned
- 2016-06-12 CN CN201680034398.8A patent/CN107949571A/zh active Pending
- 2016-06-12 RU RU2018100549A patent/RU2734169C2/ru active
- 2016-06-12 CA CA2988641A patent/CA2988641A1/en not_active Abandoned
- 2016-06-12 RU RU2018100545A patent/RU2757489C2/ru active
- 2016-06-12 EP EP16806873.2A patent/EP3307297A4/en not_active Withdrawn
-
2018
- 2018-10-16 HK HK18113250.8A patent/HK1254289A1/zh unknown
-
2023
- 2023-05-18 US US18/319,817 patent/US20240002515A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL304117A (en) | Anti-pvrig antibodies and methods of use | |
HK1258058A1 (zh) | 抗tigit抗體和使用方法 | |
HK1252858A1 (zh) | 抗cll-1抗體和使用方法 | |
HK1254289A1 (zh) | 調控免疫反應的方法及抗體 | |
HK1243102A1 (zh) | 抗cd79b抗體和使用方法 | |
HRP20181359T1 (hr) | Anti-jagged1 protutijela i postupci uporabe | |
IL258528A (en) | Gene expression modulation and dysregulated protein expression scanning | |
EP3218483A4 (en) | Compounds and methods for the modulation of proteins | |
HK1254743A1 (zh) | 新穎抗密封蛋白抗體及使用方法 | |
HK1226093B (zh) | 用於調整肌腱癒合的材料和方法 | |
GB2546719B (en) | Modulation of gene expression and screening for deregulated protein expression | |
HK1258850A1 (zh) | 抗tpbg抗體及使用方法 | |
PT3377106T (pt) | Modulação da ciliogénese |